Since May 2022,a severe global Mpox epidemic has underscored the urgent need for a preventative vaccine.On September 16,2022,the mainland of China reported its first case of imported Mpox,which was subsequently follow...Since May 2022,a severe global Mpox epidemic has underscored the urgent need for a preventative vaccine.On September 16,2022,the mainland of China reported its first case of imported Mpox,which was subsequently followed by a significant rise in domestic infections commencing from June 2023.This alarming trend has escalated the likelihood of localized outbreaks and covert transmission,posing a heightened risk to public health.Notably,the United States,many European countries,and Japan have approved the use of smallpox vaccines for Mpox prevention and emergency vaccination post-exposure,based on their cross-protection efficacy.In recent years,virology research has broadened its scope to include investigations into various novel vaccine approaches,such as nucleic acid-based vaccines,protein subunit vaccines,and epitope peptide vaccines,and other related methodologies.This review offers a thorough examination of the current global landscape of Mpox prevalence,delves into the advancements in Mpox vaccine development,and highlights the progress achieved in Mpox vaccine research,serving as a valuable resource and providing technical insights essential for the effective prevention and control of Mpox.展开更多
In 2022,a global outbreak of mpox was anticipated,with several cases reported in non-endemic countries in early May.Given the challenge of distinguishing the mpox virus(MPXV)from other pathogens based solely on sympto...In 2022,a global outbreak of mpox was anticipated,with several cases reported in non-endemic countries in early May.Given the challenge of distinguishing the mpox virus(MPXV)from other pathogens based solely on symptoms,there is an urgent need for prompt and reliable MPXV detection methods.In this study,we developed assays using recombinase-aided amplification(RAA)to identify MPXV and evaluated their applicability with clinical samples.The assays were designed to detect theN4R gene of MPXV.All assays demonstrated detection limits of 1 copy/μL within the reaction system and exhibited no cross-reactivity with ectromelia or the TianTan strain of vaccinia virus,confirming their high specificity.Our established assay provides results in less than 50 min.Furthermore,we evaluated our assay using clinical samples from laboratory-confirmed mpox patients and demonstrated that the RAA-based assay is valuable for diagnosing MPXV infections in field and clinic settings,especially in areas with limited laboratory resources.Overall,three RAA-based nucleic acid assays for MPXV were established,providing a powerful tool for efficient,rapid,and specific detection of MPXV infection.展开更多
文摘Since May 2022,a severe global Mpox epidemic has underscored the urgent need for a preventative vaccine.On September 16,2022,the mainland of China reported its first case of imported Mpox,which was subsequently followed by a significant rise in domestic infections commencing from June 2023.This alarming trend has escalated the likelihood of localized outbreaks and covert transmission,posing a heightened risk to public health.Notably,the United States,many European countries,and Japan have approved the use of smallpox vaccines for Mpox prevention and emergency vaccination post-exposure,based on their cross-protection efficacy.In recent years,virology research has broadened its scope to include investigations into various novel vaccine approaches,such as nucleic acid-based vaccines,protein subunit vaccines,and epitope peptide vaccines,and other related methodologies.This review offers a thorough examination of the current global landscape of Mpox prevalence,delves into the advancements in Mpox vaccine development,and highlights the progress achieved in Mpox vaccine research,serving as a valuable resource and providing technical insights essential for the effective prevention and control of Mpox.
基金supported by the Beijing Natural Science Foundation(7254390)the Youth Science Foundation of the Chinese Center for Disease Control and Prevention(2024A103)the National Key R&D Program of China(2022YFC2303400).
文摘In 2022,a global outbreak of mpox was anticipated,with several cases reported in non-endemic countries in early May.Given the challenge of distinguishing the mpox virus(MPXV)from other pathogens based solely on symptoms,there is an urgent need for prompt and reliable MPXV detection methods.In this study,we developed assays using recombinase-aided amplification(RAA)to identify MPXV and evaluated their applicability with clinical samples.The assays were designed to detect theN4R gene of MPXV.All assays demonstrated detection limits of 1 copy/μL within the reaction system and exhibited no cross-reactivity with ectromelia or the TianTan strain of vaccinia virus,confirming their high specificity.Our established assay provides results in less than 50 min.Furthermore,we evaluated our assay using clinical samples from laboratory-confirmed mpox patients and demonstrated that the RAA-based assay is valuable for diagnosing MPXV infections in field and clinic settings,especially in areas with limited laboratory resources.Overall,three RAA-based nucleic acid assays for MPXV were established,providing a powerful tool for efficient,rapid,and specific detection of MPXV infection.
